Verano Holdings (VRNO) Income towards Parent Company (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Income towards Parent Company of -$17.8 million for Q1 2026, down 54.78% year-over-year from -$39.4 million in Q1 2025, and up 90.28% quarter-over-quarter from -$183.4 million in Q4 2025.
Verano Holdings (VRNO) Income towards Parent Company (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Income towards Parent Company for 6 consecutive years, with -$17.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 54.78% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$264.2 million (up 24.2% YoY), while the FY2025 annual figure was -$257.9 million, up 24.56% from the prior year.
- Income towards Parent Company grew to -$17.8 million in Q1 2026 per VRNO's latest filing, from -$183.4 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $45.9 million in Q1 2022 and bottomed at -$272.7 million in Q4 2024.
- Historically, Income towards Parent Company has averaged -$56.4 million across 5 years, with a median of -$19.2 million in 2025.
- On a YoY basis, Income towards Parent Company climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
- Verano Holdings' Income towards Parent Company stood at -$216.1 million in 2022, then jumped by 64.24% to -$77.3 million in 2023, then sank by 252.85% to -$272.7 million in 2024, then surged by 32.74% to -$183.4 million in 2025, then jumped by 90.28% to -$17.8 million in 2026.
- Business Quant data shows VRNO's Income towards Parent Company at -$17.8 million in Q1 2026, -$183.4 million in Q4 2025, and -$43.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Verano Holdings | 445.39 Mn | 360.20 Mn | 99.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.41 Mn |
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -183.41 Mn |
| Sep 30, 2025 | -43.83 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -11.52 Mn |
| Dec 31, 2024 | -272.71 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -21.76 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -77.29 Mn |
| Sep 30, 2023 | -17.76 Mn |
| Jun 30, 2023 | -13.06 Mn |
| Mar 31, 2023 | -9.24 Mn |
| Dec 31, 2022 | -216.11 Mn |
| Sep 30, 2022 | -42.99 Mn |
| Jun 30, 2022 | -9.85 Mn |
| Mar 31, 2022 | 45.87 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -11.96 Mn |